Fibrous dysplasia: Difference between revisions

Jump to navigation Jump to search
Sunny Kumar (talk | contribs)
Sunny Kumar (talk | contribs)
Line 171: Line 171:
*Patients with FD usually appear normal unless the is any bony deformity or skin is involved.
*Patients with FD usually appear normal unless the is any bony deformity or skin is involved.
*Physical examination may be remarkable according to the classification of disease:
*Physical examination may be remarkable according to the classification of disease:
:*[finding 1]
:Monostetic
:*[finding 2]
:* Single bone involved
:*[finding 3]
:* Mostly affects rib, femur, and tibia.
:*[finding 4]
:* Carinofasical bone and humorus bone
:*[finding 5]
:* Fracture at age of 10 years
:*[finding 6]
:* Bone defrmity less sever
:* painless swelling of jaw
:* swelling involve buccal and labial plate
:* Protuberance of inferior border of mandible
:Polyostetic
:* Multiple bones involved
:* Involve rib, femur, clavicle, femur, lumber spine and tibia.
:* Asymmetrical involvement
:* Mainly maalignment of bones
:* Tenderness over involved bone
:* Bowing of weight bearing bone and increased curvature of femur and tibia
:Cranofasical
:* Involvement of maxilofascial bones
:* Maladjustment
:* Tappering
:* Daisplacemnt
:* Intact over lesion
:* Maxillary sinus and Zygomatic bone involved mostly
:* Floor of orbit may extend to skull
:* No extracranial involvement
:* Hypertelorisum, facial asymmetry, visual impairment, expothalmus and blindness
:* Vestibular dysfuntion, hearing loss and tinnitus.
:McCune-Albright syndrome
:* Involves all the bone of body
:* Cafe au lait spots
:* Endocrine abnormality of parathyroid hormone, gonadotropins Mazabraud syndrome
:* Involve variable number of bones
:* Cafe au lait spots
:
=== Laboratory Findings ===
=== Laboratory Findings ===
*There are no specific laboratory findings associated with [disease name].
*There are no specific laboratory findings associated with FD however we may find normal PTH, Ca levels, and increased levels of ALK phosphate due to increased bone turn over and increased BMR.
 
*A  [positive/negative] [test name] is diagnostic of [disease name].
*An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
*Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
===Imaging Findings===
===Imaging Findings===
*There are no [imaging study] findings associated with [disease name].
*Radiology is the imaging modality of choice for FD.
*On Xray, FD is characterized by  
*[Imaging study 1] is the imaging modality of choice for [disease name].
**Network of fine bone trabeculae
*On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
**Increased  trabeculation
*[Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
**Opaque  trabeculation forming ground glass appearance
**Cortical thinning
**Root of teeth separated
   
   
=== Other Diagnostic Studies ===
=== Other Diagnostic Studies ===
*[Disease name] may also be diagnosed using [diagnostic study name].
*Work up of FD may also be involve  using MRI and CT.
*Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
*Bone biopsy will revel the histological findings of as:
**Curvilinear trabeculae (Chinese letters) of metaplastic woven bone (never matures) in hypocellular,
**fibroblastic stroma
**No osteoblastic rimming (due to maturation arrest), 20% of cases have cartilaginous nodules (particularly in femoral neck region)
**Also myxoid areas, rapidly growing secondary aneurysmal bone cysts, hemorrhage, foamy macrophages, calcified spherules (similar to cementifying fibromas), cellular areas, focal hyaline cartilage or cystic areas
   
   
== Treatment ==
== Treatment ==
=== Medical Therapy ===
=== Medical Therapy ===
*There is no treatment for [disease name]; the mainstay of therapy is supportive care.
*The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
*The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
*[Medical therapy 1] acts by [mechanism of action 1].
*[Medical therapy 1] acts by [mechanism of action 1].

Revision as of 16:45, 20 April 2018

WikiDoc Resources for Fibrous dysplasia

Articles

Most recent articles on Fibrous dysplasia

Most cited articles on Fibrous dysplasia

Review articles on Fibrous dysplasia

Articles on Fibrous dysplasia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fibrous dysplasia

Images of Fibrous dysplasia

Photos of Fibrous dysplasia

Podcasts & MP3s on Fibrous dysplasia

Videos on Fibrous dysplasia

Evidence Based Medicine

Cochrane Collaboration on Fibrous dysplasia

Bandolier on Fibrous dysplasia

TRIP on Fibrous dysplasia

Clinical Trials

Ongoing Trials on Fibrous dysplasia at Clinical Trials.gov

Trial results on Fibrous dysplasia

Clinical Trials on Fibrous dysplasia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fibrous dysplasia

NICE Guidance on Fibrous dysplasia

NHS PRODIGY Guidance

FDA on Fibrous dysplasia

CDC on Fibrous dysplasia

Books

Books on Fibrous dysplasia

News

Fibrous dysplasia in the news

Be alerted to news on Fibrous dysplasia

News trends on Fibrous dysplasia

Commentary

Blogs on Fibrous dysplasia

Definitions

Definitions of Fibrous dysplasia

Patient Resources / Community

Patient resources on Fibrous dysplasia

Discussion groups on Fibrous dysplasia

Patient Handouts on Fibrous dysplasia

Directions to Hospitals Treating Fibrous dysplasia

Risk calculators and risk factors for Fibrous dysplasia

Healthcare Provider Resources

Symptoms of Fibrous dysplasia

Causes & Risk Factors for Fibrous dysplasia

Diagnostic studies for Fibrous dysplasia

Treatment of Fibrous dysplasia

Continuing Medical Education (CME)

CME Programs on Fibrous dysplasia

International

Fibrous dysplasia en Espanol

Fibrous dysplasia en Francais

Business

Fibrous dysplasia in the Marketplace

Patents on Fibrous dysplasia

Experimental / Informatics

List of terms related to Fibrous dysplasia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Fibrous dysplasia is a disorder of bones which may occur with or without endocrinological and skin disorders. It may cause bony pain, deformity, fracture and / or entrapment of nerves, It is basically the acquired mis-sense mutation of gene coding for the α-subunit of the stimulatory G-protein, Gs, in the guanine nucleotide binding, alpha stimulating (GNAS) complex locus in chromosome 20q13. It leads to immature or poor differentiation of body tissue at the time of ossification and replacement of bone by fibrous tissue. Diagnosis depends on radiology and biopsic specimen.

Historical Perspective

  • Fibrous dyspepsia was first observed in bone radiography by Von Recklinghausen in 1891.
  • It was then entitled as separate entity by american pathologist Dr. Louis Lichtenstein in 1938 as fibrous dyspepsia polyostotic.
  • In 1942, Dr Lichtenstein and Dr. Jaffe together labeled syndrome named McCune-Albright syndrome (fibrous dysplasia-café au lait spots-endocrine dysfunction) or Mazabraud syndrome (fibrous dysplasia-myxomas). 

Classification

  • Fibrous dyspepsia may be classified according to number of bony sites involved into two groups:
  • Monoostiotic
  • Polyostiotic
  • Other variants of FD include McCune-Albright syndrome, and Mazabraud syndrome.

Pathophysiology

The pathophsiology of FD is based on mechanism mutation of Gs protein.

Genetics

  • The somatic mutation in GNAS1 gene located on the long arm (q) of chromosome 20 (20q13.2)  has been associated with the development of FD, involving the gain-of-function mutation pathway.
  • As it is somatic mutation that is why it is not heritable, post fertilization mutation occurring due to unknown reason.
  • Mutation of GNAS1 gene results in the overproduction of this G-protein, which in turn increases cyclic adenosine monophosphate (cAMP).
  • cyclic adenosine monophosphate (cAMP) is important regulatory molecule of differentiation modulating osteoblasts and osteoclasts while ossification and remodeling of bones.
  • Improper differentiation of osteoblasts due to mutation of the GNAS1 gene is the cause of FD.
  • Osteoclasts removes ossified bones and creates space for immature osteoblasts to produce fibrous tissue and occupy space which may entrap nerves causing pain or nurological deficit depending on the site involved.
  • On gross pathology, Well circumscribed, intramedullary,Tan-white-yellow, gritty, Large lesions distort bone, Cortical bone often thin and expanded are characteristic findings of FD.
  • On microscopic histopathological analysis :
    • Curvilinear trabeculae (Chinese letters) of metaplastic woven bone (never matures) in hypocellular,
    • fibroblastic stroma
    • No osteoblastic rimming (due to maturation arrest), 20% of cases have cartilaginous nodules (particularly in femoral neck region)
    • Also myxoid areas, rapidly growing secondary aneurysmal bone cysts, hemorrhage, foamy macrophages, calcified spherules (similar to cementifying fibromas), cellular areas, focal hyaline cartilage or cystic areas
    • Usually abrupt transition of normal to abnormal bone
    • No/rare mitotic figures, no atypia (rarely is degenerative)
    • Overall resembles endochondral ossification in skull are characteristic findings of FD.

Clinical Features

There are four varriets of FD and the clinical features are pertaining to that specific feature.

  • Monoostiotic
  • Polyostiotic
  • McCune-Albright syndrome
  • Mazabraud syndrome

Differentiating Fibrous dyspepsia from other Diseases

  • Fibrous dyspepsia must be differentiated from other diseases that cause bone pain, deformity, and extra-skeletal involvement, such as:
Disease Bone involvement Bone pain Fever Fractures Mechanisum ALK levels Diagnosis
ossifying sarcoma single yes no yes neoplasm normal radiology and biopsy
paget's disease multiple yes no yes malfunction of

osteoblast

high biopsy
osteosarcoma single yes no yes neoplasm normal radiology and biopsy
cherubism single yes no no malfunction of

osteoblas

high radiology and biopsy
hyperparathyroidisum multiple yes yes yes high PTH normal hormone workup
solitary endocytosis single yes no no neoplasm normal radiology and biopsy
osteoblastoma single yes no yes neoplasm high radiology and biopsy
osteomyelitis single yes yes no infection normal radiology and biopsy
brodie's abscess single yes yes no infection normal radiology and biopsy

Epidemiology and Demographics

  • The prevalence and incidence of FD is not known exactly.

Age

  • FD is more commonly found in age group from 3 -15 years of life.
  • Polyostiotic does not become symptomatic before age 10 years.
  • Monostiotic is asymptomatic until age of 20-30 years of life.

Gender

  • FD affects men and women equally.

Race

  • There is no racial predilection for FD.

Risk Factors

  • Common risk factor in the development of PD is gain in function mutation.

Natural History, Complications and Prognosis

  • The majority of patients with FD remain asymptomatic for first decade of life.
  • Early clinical features include bone pain, bony deformity, fever, pathological fractures, and skin/endocrine/malignancies depending on the variant.
  • Common complications of FD include neurological deficit, endocrine abnormality, and in rare cases soft tissue tumors.
  • Prognosis is generally good, and the patients with polyostetic form may have frequent fractures.

Diagnosis

Diagnostic Criteria

  • The diagnosis of FD is made when on the basis of history, radiology findings and genetic testing to verify presence og GNAS mutation.

Symptoms

  • FD is usually asymptomatic.
  • Symptoms of FD may include Early clinical features include bone pain, bony deformity, fever, pathological fractures, and skin/endocrine/malignancies depending on the variant. Common complications of FD include neurological deficit, endocrine abnormality, and in rare cases soft tissue tumors

Physical Examination

  • Patients with FD usually appear normal unless the is any bony deformity or skin is involved.
  • Physical examination may be remarkable according to the classification of disease:
Monostetic
  • Single bone involved
  • Mostly affects rib, femur, and tibia.
  • Carinofasical bone and humorus bone
  • Fracture at age of 10 years
  • Bone defrmity less sever
  • painless swelling of jaw
  • swelling involve buccal and labial plate
  • Protuberance of inferior border of mandible
Polyostetic
  • Multiple bones involved
  • Involve rib, femur, clavicle, femur, lumber spine and tibia.
  • Asymmetrical involvement
  • Mainly maalignment of bones
  • Tenderness over involved bone
  • Bowing of weight bearing bone and increased curvature of femur and tibia
Cranofasical
  • Involvement of maxilofascial bones
  • Maladjustment
  • Tappering
  • Daisplacemnt
  • Intact over lesion
  • Maxillary sinus and Zygomatic bone involved mostly
  • Floor of orbit may extend to skull
  • No extracranial involvement
  • Hypertelorisum, facial asymmetry, visual impairment, expothalmus and blindness
  • Vestibular dysfuntion, hearing loss and tinnitus.
McCune-Albright syndrome
  • Involves all the bone of body
  • Cafe au lait spots
  • Endocrine abnormality of parathyroid hormone, gonadotropins Mazabraud syndrome
  • Involve variable number of bones
  • Cafe au lait spots

Laboratory Findings

  • There are no specific laboratory findings associated with FD however we may find normal PTH, Ca levels, and increased levels of ALK phosphate due to increased bone turn over and increased BMR.

Imaging Findings

  • Radiology is the imaging modality of choice for FD.
  • On Xray, FD is characterized by
    • Network of fine bone trabeculae
    • Increased trabeculation
    • Opaque trabeculation forming ground glass appearance
    • Cortical thinning
    • Root of teeth separated

Other Diagnostic Studies

  • Work up of FD may also be involve using MRI and CT.
  • Bone biopsy will revel the histological findings of as:
    • Curvilinear trabeculae (Chinese letters) of metaplastic woven bone (never matures) in hypocellular,
    • fibroblastic stroma
    • No osteoblastic rimming (due to maturation arrest), 20% of cases have cartilaginous nodules (particularly in femoral neck region)
    • Also myxoid areas, rapidly growing secondary aneurysmal bone cysts, hemorrhage, foamy macrophages, calcified spherules (similar to cementifying fibromas), cellular areas, focal hyaline cartilage or cystic areas

Treatment

Medical Therapy

  • The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
  • [Medical therapy 1] acts by [mechanism of action 1].
  • Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for [disease name].
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
  • [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

  • There are no primary preventive measures available for [disease name].
  • Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

References

Template:WS Template:WH